Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA EBITDA Margin

EBITDA as a percentage of revenue.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin not reported for Q2 FY2026

Over 3 fiscal years it widened by 5281.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of -9869.8% for the fiscal year ending Dec 2026, down from -1102.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
-1102.9%-47.5 pp YoY
LTMJun 2026
-2712.3%-1582.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-47.5 pp-8766.9 pp-8719.4 pp
3 years+5281.1 pp+1035.7 pp-4245.4 pp
5 years+1155.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1102.9%
Year-over-year change
-47.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's LTM Jun 2026 EBITDA Margin of -2712.3% is the lowest of the 6 companies compared; the peer median is -185.2%.
  • Its year-over-year change of -1582.7 pp is the lowest of 5, against a peer median of -86.3 pp.
  • Over three fiscal years its change of +5281.1 pp compares with a peer median of +138.5 pp.
TSHA Competitors Peer median
EBITDA Margin for TSHA and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026505.0% —+3781.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-185.2% +738962.6 pp+3203.1 pp
RGNXREGENXBIO Inc.LTM Mar 2026-261.2% -183.0 pp+138.5 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-308.4% -186.1 pp-189.2 pp
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-2712.3% -1582.7 pp+5281.1 pp
NGNENeurogene Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding TSHA) -185.2%-86.3 pp+138.5 pp

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.5M15.45M8.33M9.77M
Cost of Revenue02.49M000
Gross Profit015K15.45M8.33M9.77M
Gross Margin—0.6%100.0%100.0%100.0%
Research & Development131.94M91.17M56.78M66M86.4M
Selling, General & Admin41.32M34.87M30.05M28.95M33.87M
Operating Expenses173.27M126.04M87.89M99.79M120.27M
Depreciation & Amortization492K2.49M1.37M1.25M1.15M
EBITDA(172.6M)(159.73M)(105.2M)(87.95M)(107.79M)
EBITDA Margin—-6384.1%-680.8%-1055.5%-1102.9%
Operating Income(173.27M)(126.03M)(72.44M)(91.46M)(110.5M)
Operating Margin—-5037.1%-468.8%-1097.6%-1130.6%
Interest Income172K249K3.57M6.94M9.22M
Interest Expense1.43M3.8M5M102K63K
Other Income / Expenses(1.26M)(39.99M)(39.13M)2.16M1.5M
Income Before Tax(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Pre-Tax Margin—-6635.3%-722.1%-1071.6%-1115.3%
Income Tax Expense00000
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Net Margin—-6635.3%-722.1%-1071.6%-1115.3%
EPS (Basic)(4.64)(3.78)(0.96)(0.36)(0.34)
EPS (Diluted)(4.64)(3.78)(0.96)(0.36)(0.34)
Weighted Avg Shares37.65M43.95M116.12M250.13M319.71M
Weighted Avg Shares (Diluted)37.65M43.95M116.12M250.13M319.71M

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.